{"title":"基于临床和超声检查标准的来曲唑诱导多囊卵巢综合征不孕妇女排卵个体化剂量：一项队列研究。","authors":"Pratyasha Peepal, Padmalaya Thakur, Anubhuti Patel, Jyotiranjan Sahoo, Sujata Pradhan, Manisha Sahu","doi":"10.4103/jhrs.jhrs_72_25","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Conventionally, letrozole for ovulation induction (OI) in polycystic ovary syndrome (PCOS) is started at a dose of 2.5 mg, which is gradually escalated depending on the follicular response. The minimum dose required for follicular response for a particular patient is yet to be determined.</p><p><strong>Aim: </strong>The aim of the study was to compare various clinical and ultrasonographic characteristics of patients with successful OI with different doses of letrozole and individualise the dose of letrozole.</p><p><strong>Setting and design: </strong>This prospective cohort study was conducted in a tertiary care teaching hospital from December 2019 to March 2024.</p><p><strong>Materials and methods: </strong>Ninety-seven patients were treated with a starting dose of 2.5 mg of letrozole. The dose was increased to 5 and 7.5 mg without a follicular response. Various clinical and ultrasonographic characteristics were compared.</p><p><strong>Statistical analysis used: </strong>Data entered in Microsoft Excel and analysed using SPSS version 27. <i>P</i> < 0.05 was statistically significant.</p><p><strong>Results: </strong>Of 97 patients, 10 were lost to follow-up. Eighty-one (93.1%) patients had a positive response to letrozole. Six (6.9%) patients did not respond to the maximum dose of 7.5 mg of letrozole. Waist circumference, maximum antral follicle count per ovary and volume of the largest ovary were significantly different for patients who responded to different doses of letrozole (<i>P</i> < 0.05). Further analysis revealed that an ovarian volume of 10 cc or more is a risk factor for non-response to 2.5 mg of letrozole.</p><p><strong>Conclusion: </strong>The ovarian volume can be considered when determining the dose of letrozole in PCOS.</p>","PeriodicalId":15975,"journal":{"name":"Journal of Human Reproductive Sciences","volume":"18 2","pages":"89-95"},"PeriodicalIF":1.1000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12306715/pdf/","citationCount":"0","resultStr":"{\"title\":\"Individualisation of the Dose of Letrozole for Ovulation Induction in Infertile Women with Polycystic Ovary Syndrome Based on Clinical and Ultrasonography Criteria: A Cohort Study.\",\"authors\":\"Pratyasha Peepal, Padmalaya Thakur, Anubhuti Patel, Jyotiranjan Sahoo, Sujata Pradhan, Manisha Sahu\",\"doi\":\"10.4103/jhrs.jhrs_72_25\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Conventionally, letrozole for ovulation induction (OI) in polycystic ovary syndrome (PCOS) is started at a dose of 2.5 mg, which is gradually escalated depending on the follicular response. The minimum dose required for follicular response for a particular patient is yet to be determined.</p><p><strong>Aim: </strong>The aim of the study was to compare various clinical and ultrasonographic characteristics of patients with successful OI with different doses of letrozole and individualise the dose of letrozole.</p><p><strong>Setting and design: </strong>This prospective cohort study was conducted in a tertiary care teaching hospital from December 2019 to March 2024.</p><p><strong>Materials and methods: </strong>Ninety-seven patients were treated with a starting dose of 2.5 mg of letrozole. The dose was increased to 5 and 7.5 mg without a follicular response. Various clinical and ultrasonographic characteristics were compared.</p><p><strong>Statistical analysis used: </strong>Data entered in Microsoft Excel and analysed using SPSS version 27. <i>P</i> < 0.05 was statistically significant.</p><p><strong>Results: </strong>Of 97 patients, 10 were lost to follow-up. Eighty-one (93.1%) patients had a positive response to letrozole. Six (6.9%) patients did not respond to the maximum dose of 7.5 mg of letrozole. Waist circumference, maximum antral follicle count per ovary and volume of the largest ovary were significantly different for patients who responded to different doses of letrozole (<i>P</i> < 0.05). Further analysis revealed that an ovarian volume of 10 cc or more is a risk factor for non-response to 2.5 mg of letrozole.</p><p><strong>Conclusion: </strong>The ovarian volume can be considered when determining the dose of letrozole in PCOS.</p>\",\"PeriodicalId\":15975,\"journal\":{\"name\":\"Journal of Human Reproductive Sciences\",\"volume\":\"18 2\",\"pages\":\"89-95\"},\"PeriodicalIF\":1.1000,\"publicationDate\":\"2025-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12306715/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Human Reproductive Sciences\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4103/jhrs.jhrs_72_25\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/6/20 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Human Reproductive Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/jhrs.jhrs_72_25","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/20 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
Individualisation of the Dose of Letrozole for Ovulation Induction in Infertile Women with Polycystic Ovary Syndrome Based on Clinical and Ultrasonography Criteria: A Cohort Study.
Background: Conventionally, letrozole for ovulation induction (OI) in polycystic ovary syndrome (PCOS) is started at a dose of 2.5 mg, which is gradually escalated depending on the follicular response. The minimum dose required for follicular response for a particular patient is yet to be determined.
Aim: The aim of the study was to compare various clinical and ultrasonographic characteristics of patients with successful OI with different doses of letrozole and individualise the dose of letrozole.
Setting and design: This prospective cohort study was conducted in a tertiary care teaching hospital from December 2019 to March 2024.
Materials and methods: Ninety-seven patients were treated with a starting dose of 2.5 mg of letrozole. The dose was increased to 5 and 7.5 mg without a follicular response. Various clinical and ultrasonographic characteristics were compared.
Statistical analysis used: Data entered in Microsoft Excel and analysed using SPSS version 27. P < 0.05 was statistically significant.
Results: Of 97 patients, 10 were lost to follow-up. Eighty-one (93.1%) patients had a positive response to letrozole. Six (6.9%) patients did not respond to the maximum dose of 7.5 mg of letrozole. Waist circumference, maximum antral follicle count per ovary and volume of the largest ovary were significantly different for patients who responded to different doses of letrozole (P < 0.05). Further analysis revealed that an ovarian volume of 10 cc or more is a risk factor for non-response to 2.5 mg of letrozole.
Conclusion: The ovarian volume can be considered when determining the dose of letrozole in PCOS.
期刊介绍：
The Journal of Human Reproductive Sciences (JHRS) (ISSN:0974-1208) a Quarterly peer-reviewed international journal is being launched in January 2008 under the auspices of Indian Society of Assisted Reproduction. The journal will cover all aspects human reproduction including Andrology, Assisted conception, Endocrinology, Physiology and Pathology, Implantation, Preimplantation Diagnosis, Preimplantation Genetic Diagnosis, Embryology as well as Ethical, Legal and Social issues. The journal will publish peer-reviewed original research papers, case reports, systematic reviews, meta-analysis, and debates.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
